GSK said it will pay CureVac 400 million euros ($429.44 million) upfront and up to an additional 1.05 billion euros ($1.13 billion) in development, regulatory and sales milestones as well as tiered royalties.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/BAD6u8L
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment